Innolake Biopharm

Private

HangzhouHealthcare & Life Scienceshttps://www.innolakebio.com/

Last Round

Series A

Extension

Jun 5, 2023

Total Funding Raised

$53.99M

Company Overview

Innolake Biopharm is a clinical-stage biotechnology company that develops therapeutic drugs for cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugateADConcology drug developmentbiotech licensingmonoclonal antibodiessmall molecule discoveryclinical-stage biotechautoimmune disease therapeuticsdrug discovery platformfirst-in-class drugsbiopharma partneringout-licensingsolid tumor treatmentB7H3 inhibitorA2aR antagonist

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Innolake Biopharm Comps

Public and private peers based on sector, stage, and business model.

Innolake Biopharm comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Innolake Biopharm Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A Extension	Jun 5, 2023
Early Funding	Apr 6, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Mingde Xia

Founder, Chairman And CEO

Founding Team

Innolake Biopharm Investors

Notable investors and investment history

Innolake Biopharm investors
Investor	Rounds
Zhongbo Juli	Series A Extension
Hangzhou Heda Industry Fund	Series A Extension
Huagai Capital	Early Funding
CDH Investments	Early Funding
Zhongbo Venture Capital	Series A Extension

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jun 5, 2023
$14M round led by Zhongbo Juli and Hangzhou Heda Industry Fund.

View all signals

Innolake Biopharm Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Innolake Biopharm Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Innolake Biopharm's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou

Employee Range5

Year Founded2020

Last FundingJun 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.